Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the ability of darbepoetin alfa to maintain hemoglobin
concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W).